Chronic myeloid leukemia (CML) is primarily caused by the oncogenic fusion protein BCR-ABL, and tyrosine kinase inhibitors (TKIs) have shown potent efficacy in the treatment of CML. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.